Interferon beta-1a extended release - Merck Serono

Drug Profile

Interferon beta-1a extended release - Merck Serono

Latest Information Update: 19 Mar 2012

Price : $50

At a glance

  • Originator Merck Serono
  • Class Antineoplastics; Antivirals; Interferons; Proteins
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2011 Flamel Technologies completes a phase I trial in Multiple sclerosis in France
  • 11 Mar 2011 Phase-I development is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top